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Abstract: We report the design and synthesis of a new diazepine derivative, 4-(4-methoxyphenyl)-
2,3,4,5-tetrahydro-2,3-benzodiazepin-1-one (VBZ102), and the evaluation of its anxiolytic-like profile,
memory impairment effect, and toxicity in Swiss mice. VBZ102 was evaluated for central nervous
system effects in an open field, light–dark box, and novel object recognition tests under oral ad-
ministration for acute and sub-acute treatment. We tested the VBZ102 toxicity in mice through a
determination of LD50 values and examination of the biochemical and histopathological parameters.
The VBZ102 induced an anxiolytic effect at different doses both in the light–dark box and open
field tests. Unlike other benzodiazepines (e.g., bromazepam), a sedative effect was noted only after
administration of the VBZ102 at 10.0 mg/kg.
Keywords: benzodiazepines; central nervous system; mouse behavioral model; toxicity
1. Introduction
Anxiety is a normal physiological state that is beneficial in certain dangerous life
situations and triggers the fight or flight stress response and physical symptoms resulting
from the autonomic nervous system response. However, anxiety may transform into a
mental illness when it becomes chronic, irrational, and interferes with many life func-
tions [1]. A majority of drugs used in anxiety treatment represent positive modulators of
the gamma-aminobutyric acid (GABA) transmission, including benzodiazepine derivatives,
and selective serotonin reuptake inhibitors (SSRIs) of different chemical natures [2,3].
The interest of medicinal chemists in 2,3-benzodiazepines (2,3BDZs) has exhibited
an exponential growth since the discovery of their action as noncompetitive α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists endowed with
anticonvulsant and neuroprotective properties. A number of active molecules of this type
have been synthesized over the past 40 years. Some of those compounds, e.g., tofisopam
(Grandaxin®), girisopam, nerisopam, possess significant anxiolytic and antipsychotic
activities (Figure 1) [4]. Along with those, the compounds in question are known to have
unwanted side-effects, such as an anterograde memory loss [5,6]. Therefore, there is a
pressing need for the development of new active compounds with favorable side-effect
profiles, credible benefits, and moderate costs. In the search for alternative and more
specific molecules, current investigations are focused on the anxiolytic, sedative, and
locomotor activities of various benzodiazepine derivatives. For example, new potent
anxiolytic dibenz-(1,4)-diazepin-1-one derivatives were recently synthesized [7].
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Figure 1. 2,3-Benzodiazepines with anxiolytic activity. 
The biological activity of a molecule is largely governed by its geometry. The latter 
itself is mainly controlled by a core scaffold, and the substituents play only a minor role 
[8,9]. However, current commercial databases used for drug discovery lack 3D scaffolds 
and mostly consist of linear or planar sp2-rich ones [9,10]. Therefore, the development of 
new geometrically diverse scaffolds is of vital importance. 2,3-Benzodiazepines have a 
non-planar structure and show promising results, particularly for their 3,4-dihydro-de-
rivatives [11]. In particular, a drug candidate talampanel have shown prominent anticon-
vulsant activity [12]. 
All known successes in the development of noncompetitive AMPA receptor antago-
nists were based on modifications of the 1-aryl-2,3-benzodiazepine scaffold. Recently, we 
published a method of synthesis of 4-aryl-2,3-benzodiazepin-1-ones, which are the regioi-
somers of 1-aryl-2,3-benzodiazepine-4-ones [13]. 
The present paper is devoted to a new central nervous system (CNS)-active benzodi-
azepine derivative. We report the synthesis, pharmacological activity in mouse behavioral 
models, and toxicity evaluation of the new compound 4-(4-methoxyphenyl)-2,3,4,5-tetra-
hydro-2,3-benzodiazepin-1-one (VBZ102). 
2. Results 
2.1. Chemical Synthesis 
2,3-Benzodiazepin-1-ones 1a–c (Figure 2) were prepared according to our previously 
reported procedure [14]. Literature data on the reduction of 2,3-benzodiazepin-1-ones are 
not available. Grasso et al. [15] described the reduction of 2,3-benzodiazepin-4-ones using 
sodium cyanoborohydride in methanol. We investigated the reduction of 4-(4-methoxy-
phenyl)-2,5-dihydro-1H-2,3-benzodiazepin-1-one 1b with cyanoborohydride, borohy-
dride, and sodium trimethoxyborohydride. It was found that the reduction of the 
C(4)=N(3) double bond of the diazepine 1b proceeded selectively, and the yield of the 
diazepine 2b reached 40%. The reaction of 1b with tris-(methoxy)sodium borohydride led 
to a complex mixture of products, while the use of sodium borohydride gave the starting 
compound only. 
Figure 1. 2,3-Benzod azepines with anxiolytic activity.
The biological activity of a molecule is largely governed by its geometry. The latter it-
self is mainly controlled by a core scaffold, and the substituents play only a minor role [8,9].
However, current commercial databases used for drug discovery lack 3D scaffolds and
mostly consist of linear or planar sp2-rich ones [9,10]. Therefore, the development of new ge-
ometrically diverse scaffolds is of vital importance. 2,3-Benzodiazepines have a non-planar
structure and show promising results, partic larly for their 3,4-dihydro-derivatives [11]. In
particular, a drug candidate alampanel have shown prominent anticonvulsant activity [12].
All known successes in the development of noncompetitive AMPA receptor an ag-
onists were based on modifications of the 1-aryl-2,3-benzodiazepine scaffold. Recently,
we published a method of synthesis of 4-aryl-2,3-benzodiazepin-1-ones, which are the
regioisomers of 1-aryl-2,3-benzodiazepine-4-ones [13].
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Figure 2. Hydrogenation of 2,3-benzodiazepin-1-ones. Reagents and conditions: H2, 10 % Pd/C, 
MeOH-HCl, r.t., atmospheric pressure. 
We developed a simple and effective method of C=N bond reduction in benzodiaze-
pines 1a–c by Pd-catalyzed hydrogenation. The reaction was carried out in methanol at 
room temperature, an aqueous solution of hydrochloric acid was added to improve the 
solubility. The yields of diazepines 2a–c reached 80–90%. Both analytical and spectral data 
of all synthesized compounds were in full agreement with the proposed structures; stere-
oselectivity of the reaction was not studied. 
Taking into consideration the existing pharmacological data for the compounds of 
type 1 [16], we selected 4-(4-methoxyphenyl)-2,3,4,5-tetrahydro-2,3-benzodiazepin-1-one 
2b (VBZ102) for activity and toxicity evaluation. On one hand, that choice was also sup-
ported by the presence of only one substituent, viz. the methoxy group, which had been 
shown to decrease the toxicity of drugs [17,18]. On the other hand, the VBZ102 allowed 
us to test the activity of the scaffold itself that was not biased by the substitution pattern. 
2.2. VBZ102 Effect in the Experimental Anxiety Tests 
2.2.1. Acute Treatment 
To determine the effective dose, we used three doses of the VBZ102 in mice P.O. (0.5, 
1.0, and 10.0 mg/kg bw) in the open field and LDB tests. The results are compared with 
vehicle, negative control, and bromazepam, a reference drug. 
Open Field Test 
We studied the effect of increasing doses of the VBZ102 on the number of total 
squares crossed and the time spent in the center of the open field test box. 
The amount of 10.0 mg/kg of orally administered VBZ102 showed a significant dim-
inution of the total squares crossed (F = 169.8; p < 0.001). However, no considerable differ-
ence was observed for the doses of 0.5 mg/kg and 1.0 mg/kg of the VBZ102 when com-
pared to the vehicle (Figure 3A). 
The time spent in the center was increased at the doses of 10.0 and 1.0 mg/kg of the 
VBZ102 when compared to the vehicle and bromazepam (F = 15.82; p < 0.001) (Figure 3B). 
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We developed a simple and effective method of C=N bond reduction in benzodi-
azepines 1a–c by Pd-catalyzed hydrogenation. The reaction was carried out in methanol
at room temperature, an aqueous solution of hydrochloric acid was added to improve
the solubility. The yields of diazepines 2a–c reached 80–90%. Both analytical and spectral
data of all synthesized compounds were in full agreement with the proposed structures;
stereoselectivity of the reaction was not studied.
Taking into consideration the existing pharmacological data for the compounds of
type 1 [16], we selected 4-(4-methoxyphenyl)-2,3,4,5-tetrahydro-2,3-benzodiazepin-1-one
2b (VBZ102) for activity and toxicity evaluation. On one hand, that choice was also
supported by the presence of only one substituent, viz. the methoxy group, which had been
shown to decrease the toxicity of drugs [17,18]. On the other hand, the VBZ102 allowed us
to test the activity of the scaffold itself that was not biased by the substitution pattern.
2.2. VBZ102 Effect in the Experimental Anxiety Tests
2.2.1. Acute Treatment
To determine the effective dose, we used three doses of the VBZ102 in mice P.O. (0.5,
1.0, and 10.0 mg/kg bw) in the open field and LDB tests. The results are compared with
vehicle, negative control, and bromazepam, a reference drug.
Open Field Test
We studied the effect of increasing doses of the VBZ102 on the number of total squares
crossed and the time spent in the center of the open field test box.
The amount of 10.0 mg/kg of orally administered VBZ102 showed a significant
diminution of the total squares crossed (F = 169.8; p < 0.001). However, no considerable
difference was observed for the doses of 0.5 mg/kg and 1.0 mg/kg of the VBZ102 when
compared to the vehicle (Figure 3A).




Figure 3. Effects of VBZ102, vehicle, and bromazepam on (A) the number of total squares crossed in the open field test, 
(B) the time spent in the center in the open field test, (C) the time spent in the light area in the LDB test, and (D) the number 
of transitions in the LDB test. The data are expressed as mean ± standard deviation. The analysis was done using two-
way repeated-measures analysis of variance followed by the Tukey post-hoc test. *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05, 
compared to the respective session of the vehicle group. ### p ≤ 0.001, # p ≤ 0.05, compared to the bromazepam group. 
Light–Dark Box Test 
VBZ102 (1.0 and 10.0 mg/kg) and bromazepam (1.0 mg/kg) led to a significant in-
crease of the time spent in the light compartment (F = 433.8; p < 0.001), when compared to 
the vehicle (Figure 3C). Extended times spent in the light compartment were also observed 
for the administration of 0.5 mg/kg of the VBZ102. 
However, the number of transitions between the light and dark compartments was 
also increased (F=30.95; p < 0.001) under treatment with 1.0 mg/kg of the VBZ102, fol-
lowed by bromazepam (1.0 mg/kg) and 0.5 mg/kg dose of the VBZ102 (Figure 3D). 
2.2.2. Chronic Treatment 
Open Field Test 
In the open field test, administration of 1.0 mg/kg of the VBZ102 for 1, 7, 14, and 21 
days significantly increased the time spent in the center area (Figure 4A) but did not affect 
the number of total squares crossed (F (6,48) = 4.335; p = 0.001) (Figure 4B). 
The VBZ102 also substantially increased the time spent in the center area with respect 
to the same dose of bromazepam (Figure 4A), but there was little difference in the total 
squares crossed (F (6,24) = 13.14; p < 0.001) (Figure 4B). 
Figure 3. Effects of VBZ102, vehicle, and bromazepam on (A) the number of total squares crossed in the open field test,
(B) the time spent in the center in the open field test, (C) the time spent in the light area in the LDB test, and (D) the number
of transitions in the LDB test. The data are expressed as mean ± standard deviation. The analysis was done using two-way
repeated-m asures analysis of var a ce followed by the Tukey post-hoc test. *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05, compared
to the respective session of the vehicle group. ### p ≤ 0.001, # p ≤ 0.05, compared to the bromazepam group.
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The time spent in the center was increased at the doses of 10.0 and 1.0 mg/kg of the
VBZ102 when compared to the vehicle and bromazepam (F = 15.82; p < 0.001) (Figure 3B).
Light–Dark Box Test
VBZ102 (1.0 and 10.0 mg/kg) and bromazepam (1.0 mg/kg) led to a significant
increase of the time spent in the light compartment (F = 433.8; p < 0.001), when compared to
the vehicle (Figure 3C). Extended times spent in the light compartment were also observed
for the administration of 0.5 mg/kg of the VBZ102.
However, the number of transitions between the light and dark compartments was
also increased (F=30.95; p < 0.001) under treatment with 1.0 mg/kg of the VBZ102, followed
by bromazepam (1.0 mg/kg) and 0.5 mg/kg dose of the VBZ102 (Figure 3D).
2.2.2. Chronic Treatment
Open Field Test
In the open field test, administration of 1.0 mg/kg of the VBZ102 for 1, 7, 14, and
21 days significantly increased the time spent in the center area (Figure 4A) but did not
affect the number of total squares crossed (F (6,48) = 4.335; p = 0.001) (Figure 4B).




Figure 4. Effects of the VBZ102, vehicle, and bromazepam on (A) the time spent in the center in the open field test, (B) the 
number of total squares crossed in the open field test, (C) the time spent in the light area in the LDB test, and (D) the 
number of transitions between the light and dark compartments in the LDB test. The data are expressed as mean ± stand-
ard deviation. The analysis was done using two-way repeated-measures analysis of variance followed by the Tukey post-
hoc test. *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05, compared to the respective session of the vehicle group. ### p ≤ 0.001, ## p ≤ 
0.01, # p ≤ 0.05, compared to the bromazepam group. 
Light–Dark Box Test 
Treatment with 1.0 mg/kg of the VBZ102 increased the number of transitions and the 
time spent in the light area when compared to the negative control. The time spent in the 
light area was almost identical during the treatment period. However, the number of tran-
sition was higher in the 21 days term (F (6, 48) = 1.992; p = 0.085; F (6, 48) = 1.53; p = 0.188) 
(Figure 4C,D). 
There was no significant difference of the time spent in the light area in comparison 
to bromazepam. However, the number of transitions between the light and dark compart-
ments was increased for the mice treated with the VBZ102. 
2.3. Evolution of VBZ102 Side Effects on Memory 
Novel Object Recognition 
During the training period, all groups spent a similar time exploring the two different 
objects. In addition, there were no significant changes in the total exploration time. During 
the testing period the administration of bromazepam decreased the exploration time. 
However, a comparison of the exploration time of the familiar object vs. the novel one did 
not show any substantial difference among the groups (Figure 5). Administration of brom-
azepam decreased the time spent to explore a new object (F (6, 48) = 11.8; p < 0.001). 
Furthermore, we noted that the discrimination index for the bromazepam group was 
clearly lower than that of the VBZ102 group (F (6, 48) = 60.93; p < 0.001). 
Figure 4. Effects of the VBZ102, vehicle, and bromaze ( ) the time spent in the c nt r in the op n fi ld test, (B) he
number of total squares crossed in the open field test, t e time spent in the light are in the LDB test, and (D) the
numbe of transitions between the light and d partments in the LDB test. The data are expressed a mean ± st dard
deviation. lysis was done using two-way repeated-measures analysis of variance followed by the Tukey post-hoc
test. ** 0.0 1, ** p ≤ 0.01, * p ≤ 0.05, compared to the respective session of the vehicle group. ### p ≤ 0.001, # p ≤ 0. ,
0.0 , ared to the bromazepam group.
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The VBZ102 also substantially increased the time spent in the center area with respect
to the same dose of bromazepam (Figure 4A), but there was little difference in the total
squares crossed (F (6,24) = 13.14; p < 0.001) (Figure 4B).
Light–Dark Box Test
Treatment with 1.0 mg/kg of the VBZ102 increased the number of transitions and
the time spent in the light area when compared to the negative control. The time spent
in the light area was almost identical during the treatment period. However, the number
of transition was higher in the 21 days term (F (6, 48) = 1.992; p = 0.085; F (6, 48) = 1.53;
p = 0.188) (Figure 4C,D).
There was no significant difference of the time spent in the light area in compari-
son to bromazepam. However, the number of transitions between the light and dark
compartments was increased for the mice treated with the VBZ102.
2.3. Evolution of VBZ102 Side Effects on Memory
Novel Object Recognition
During the training period, all groups spent a similar time exploring the two different
objects. In addition, there were no significant changes in the total exploration time. During
the testing period the administration of bromazepam decreased the exploration time.
However, a comparison of the exploration time of the familiar object vs. the novel one
did not show any substantial difference among the groups (Figure 5). Administration of
bromazepam decreased the time spent to explore a new object (F (6, 48) = 11.8; p < 0.001).
Furthermore, we noted that the discrimination index for the bromazepam group was
clearly lower than that of the VBZ102 group (F (6, 48) = 60.93; p < 0.001).




Figure 5. Novel object recognition test. (A) Time spent by different groups of mice to explore the novel object. (B) Discrim-
ination index performance of different groups of mice. The data are expressed as mean ± standard deviation. The analysis 
was done using two-way repeated-measures analysis of variance followed by the Tukey post-hoc test. *** p ≤ 0.001, ** p 
≤ 0.01, compared to the vehicle group, ### p ≤ 0.001, ## p ≤ 0.01, # p ≤ 0.05, compared to the bromazepam group. 
2.4. Toxicity 
In order to assess chronic toxicity, the VBZ102 was administered orally at the doses 
of 10.0 mg/kg and 1.0 mg/kg for 21 days. No mortality and no poisoning symptoms were 
observed, except for a mildly reduced mobility reaction for the mice treated at the dose of 
10.0 mg/kg. Iridescent hair was observed during the first week of the treatment, but it 
disappeared subsequently. 
Concurrently, after 28 days, no noticeable body weight difference was observed for 
the mice of the control group and those treated with 10.0 and 1.0 mg/kg doses (Table 1). 
The relative weight of the spleen was significantly (p < 0.001) increased in the group 
treated with 10.0 mg/kg of the VBZ102 (F (2.6) = 89,34; p < 0.001), whereas that of the other 
organs remained unchanged (Table 2). Thus, our data indicate that VBZ102 did not cause 
any adverse effects on the body weight. 
Table 1. Effects of the orally administered VBZ102 on body weight (g) after 28 days of treatment. 
 Week 1 Week 2 Week 3 Week 4 
Vehicle 35.2 ± 1.2 36.0 ± 1.2 38.0 ± 2.2 37.4 ± 1.4 
VBZ102, 1.0 mg/kg 31.2 ± 2.4 32.4 ± 1.3 32.2 ± 3.1 33.2 ± 1.5 
VBZ102, 10.0 mg/kg 33.4 ± 2.2 32.2 ± 4.0 30.4 ± 2.3 37.0 ± 1.2 
Note: Values are expressed as mean ± SD of 5 mice in each group. One-way ANOVA followed by Dunnett’s post hoc test 
are used; p < 0.001 compared to control. 
Table 2. Effect of the orally administered VBZ102 on average relative organ weight (%) at the 28th day of treatment. 
 Liver Kidneys Spleen Adrenal Glands Lungs 
Vehicle 10.10 ± 0.67 1.62 ± 0.07 0.77 ± 0.09 0.40 ± 0.04 0.51 ± 0.10 
VBZ102, 1.0 mg/kg 9.71 ± 0.49 1.92 ± 0.03 0.80 ± 0.12 0.03 ± 0.03 0.56 ± 0.02 
VBZ102, 10.0mg/kg 9.13 ± 0.79 1.31 ± 0.24 5.65 ± 0.24 a 0.03 ± 0.00 0.63 ± 0.08 
Note: Values are expressed as mean ± SD of 5 mice in each group. One-way ANOVA followed by Dunnett’s post hoc test 
are used. a p < 0.001 compared to control. 
Biochemical Parameters 
Biochemical tests showed no significant differences, except for the aspartate ami-
notransferase (AST) test (F (2.6) = 0.875 p = 0.650, F (2.6) = 0.463 p = 0.649, F (2.6) = 2.723 p 
Figure 5. Novel object recognition test. (A) Time spent by different groups of mice to explore the novel object. (B) Discrimination
index perfor ance of different groups of mice. The data are expressed as mean ± standard deviation. The analysis was
done using two-way repeate - easures an lysis of variance followed by the Tukey post-hoc test. *** p ≤ 0.001, ** p ≤ 0.01,
compared t e vehicle group, ### p ≤ 0.0 1, # p ≤ 0.05, compared to the bro azepam group.
2.4. Toxicity
In order to assess chronic toxicity, the VBZ102 was administered orally at the doses of
10.0 mg/kg and 1.0 mg/kg for 21 days. No mortality and no poiso ing symptoms were
observed, except for a mildly reduced mobility reaction for the mice treated at the dose
of 10.0 mg/kg. Iridescent hair was observed during the first week of the treatment, but it
disappeared subsequently.
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Concurrently, after 28 days, no noticeable body weight difference was observed for
the mice of the control group and those treated with 10.0 and 1.0 mg/kg doses (Table 1).
The relative weight of the spleen was significantly (p < 0.001) increased in the group treated
with 10.0 mg/kg of the VBZ102 (F (2.6) = 89,34; p < 0.001), whereas that of the other organs
remained unchanged (Table 2). Thus, our data indicate that VBZ102 did not cause any
adverse effects on the body weight.
Table 1. Effects of the orally administered VBZ102 on body weight (g) after 28 days of treatment.
Week 1 Week 2 Week 3 Week 4
Vehicle 35.2 ± 1.2 36.0 ± 1.2 38.0 ± 2.2 37.4 ± 1.4
VBZ102, 1.0 mg/kg 31.2 ± 2.4 32.4 ± 1.3 32.2 ± 3.1 33.2 ± 1.5
VBZ102, 10.0 mg/kg 33.4 ± 2.2 32.2 ± 4.0 30.4 ± 2.3 37.0 ± 1.2
Note: Values are expressed as mean ± SD of 5 mice in each group. One-way ANOVA followed by Dunnett’s post
hoc test are used; p < 0.001 compared to control.
Table 2. Effect of the orally administered VBZ102 on average relative organ weight (%) at the 28th
day of treatment.
Liver Kidneys Spleen AdrenalGlands Lungs
Vehicle 10.10 ± 0.67 1.62 ± 0.07 0.77 ± 0.09 0.40 ± 0.04 0.51 ± 0.10
VBZ102, 1.0 mg/kg 9.71 ± 0.49 1.92 ± 0.03 0.80 ± 0.12 0.03 ± 0.03 0.56 ± 0.02
VBZ102, 10.0mg/kg 9.13 ± 0.79 1.31 ± 0.24 5.65 ± 0.24 a 0.03 ± 0.00 0.63 ± 0.08
Note: Values are expressed as mean ± SD of 5 mice in each group. One-way ANOVA followed by
Dunnett’s post hoc test are used. a p < 0.001 compared to control.
Biochemical Parameters
Biochemical tests showed no significant differences, except for the aspartate amino-
transferase (AST) test (F (2.6) = 0.875 p = 0.650, F (2.6) = 0.463 p = 0.649, F (2.6) = 2.723
p = 0.144) for the urea, creatinine, and ALT, respectively. The AST values increased sig-
nificantly in the group treated with the 10 mg/kg dose when compared to the vehicle
(F (2.6) = 95.22 p < 0.001) (Table 3).
Table 3. Effect of the orally administered VBZ102 on the biochemical parameters of mice.
Vehicle VBZ102, 1.0 mg/kg VBZ102, 10.0 mg/kg
Urea 0.28 ± 0.02 0.24 ± 0.01 0.38 ± 0.04
Creatinine 3.40 ± 0.31 4.00 ± 0.00 4.33 ± 0.33
ALT 45.80 ± 1.11 23.00 ± 2.52 44.33 ± 12.72
AST 311.00 ± 27.22 223.33 ± 13.33 568.00 ± 180.58 a
Note: Values are expressed as mean ± SD of 5 mice in each group. One-way ANOVA followed by Dunnett’s post
hoc test are used; a p < 0.001 compared to control.
2.5. Histological Examination
Microscopic examination of sections of different organs of the control and treated
groups showed an absence of any gross pathological lesions (Figure 6) and a normal liver
histology at the dose of 1.0 mg/kg. However, the presence of nuclear degenerescence,
vacuolation, and steatosis was noticed in the liver cells at the dose of 10 mg/kg, and the
nuclei were not centered inside the cells.
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The control group; (B,E,H) the group treated with 10.0 mg/kg of the VBZ102; (C,F,I) the group treated with 1.0 mg/kg of
the VBZ102. (A,D,G) Normal cells. (B) Nuclear degenerescence, vacuolation, and steatosis within cells; the nuclei are not
centered, although, there is no inflammatory infiltrate around the centrilobular vein. (E) Normal cells. (H) Presence of a
clear halo around perivascular halo vessels. (C) Degeneration of the plasma membrane, vacuolation, steatosis, and infiltrate
around the centrilobular vein. (F) Normal cells. (I) Normal cells (hematoxylin and eosin (H&E) ×400).
3. Discussion
The aim of this study was to evaluate the VBZ102 effect on anxiety in mice. The
doses of 0.5 mg/kg, 1.0 mg/kg, and 10.0 mg/kg were chosen to select an effective dose
that would not trigger side-effects. The dose of 0.5 mg/kg produced no significant effect.
Administration of 1.0 mg/kg of VBZ102 led to an increase both in the number of entries
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and the time spent in the light area in the LDB test, and in the time spent in the center
and number of total squares crossed in the open field. While the time spent in the light
area in the LDB test and that in the center in the open field test increased after the dose
of 10.0 mg/kg, this dose, however, provoked a decrease in both the number of transitions
in the LDB test and the number of total squares crossed in the open field test, indicating
a sedative effect. Therefore, we chose 1.0 mg/kg of VBZ102 as the effective dose and
continued the sub-acute study at that dose in the LDB and open field tests. The higher
dose of 10.0 mg/kg was used to investigate possible undesirable effects, such as memory
alteration and toxicity.
The open field test is a very popular animal model of anxiety-like behavior. It is
used to assess the locomotor behavior of mice and to detect anxiogenic- or anxiolytic-like
agents [19]. The results showed that the VBZ102 increased the time spent by the mice
in the central area of the open field test in a dose-dependent manner. At 1.0 mg/kg, the
compound under investigation induced an increase both in time spent in the central area
and the total number of square crossings, which suggests an anxiolytic-like activity. The
treatment (1.0 mg/kg) did not change the total number of crossings, the immobility time,
or the number of rearing behaviors, thereby suggesting no alteration in the locomotion
of animals.
In the light–dark box test, anxiety is generated by the conflict between desire to explore
and to retreat from an unknown and well-illuminated space [20]. Our experimental data
showed an increase in both the time spent in the light compartment and in the number
of transitions between the LDB chambers after a single dose of the VBZ102. Moreover,
after treatment for 21 days, the number of transitions between the compartments and
the time spent in the light one significantly increased. Therefore, the VBZ102 revealed a
pronounced anxiolytic effect like that of bromazepam. The anxiolytic activity mechanism
of both compounds could either be related to GABA A receptor complex or may be similar
to 2,3-benzodiazepine AMPA antagonists [11]. Our results corroborate those obtained
for other 2,3-benzodiazepine AMPA receptor antagonists (e.g., GYKI 53405 [21], GYKI
53655 [22], and EGIS-8332 [23,24]) that demonstrated their anxiolytic effects in several
behavioral tests, such as the LDB, elevated plus maze (EPM), and Vogel tests [25]. The
toxicity study revealed a significant increase in the values of AST and some change in
the histological sections of liver at the dose of 10.0 mg/kg (see Figure 6B). Therefore,
the VBZ102 at 10.0 mg/kg is capable of inducing lesions in the liver. The relative organ
weight study showed a significant increase of spleen in mice, which can be explained by
leukocytosis, extramedullary hematopoiesis, erythrophagocytosis, or septic shock [21].
However, no significant changes were observed in biochemical and histological parameters
at the dose of 1.0 mg/kg.
It is interesting to note that VBZ102 had no sedative effect at the dose of 1.0 mg/kg,
while the bromazepam is known as an anxiolytic and sedative drug [26,27]. This observa-
tion was confirmed by the increase in the number of transitions in the LDB test and no
change in the number of total squares crossed in the open field one.
To the best of our knowledge, undesirable side-effects of diazepines on memory
have not been studied, despite some negative effects being demonstrated [6,28]. In the
present study, the VBZ102 effects on learning and memory impairments were investigated.
The memory function of mice treated with VBZ102 for 21 days remained intact when
compared to bromazepam, which provokes a decrease in memory and learning capacity in
the novel object recognition test. Our data clearly demonstrated that the compound under
investigation did not show side-effects on memory in the novel object recognition tests.
4. Materials and Methods
4.1. Chemical Synthesis
4.1.1. General Experimental Procedures
The reagents and solvents were obtained from commercial suppliers and used without
further purification unless otherwise specified. All reagents were weighed and handled
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in air at room temperature, and the reactions were performed in round bottomed flasks.
Organic solutions were concentrated on a rotary evaporator at 23–35 ◦C. Melting points
(uncorrected) were determined with a capillary melting point apparatus. Proton and
carbon nuclear magnetic resonance (1H and 13C NMR) spectra were recorded with a Varian
VXR-300 (299.9 MHz) spectrometer in parts per million from internal tetramethylsilane on
the δ scale and were referenced from the residual proton or carbon resonances in the NMR
solvent (DMSO: 1H δ 2.50, 13C δ 39.5). The spectral data are reported as follows: chemical
shift, multiplicity s = singlet, d = doublet, t = triplet, m = multiplet.
4.1.2. 4-Phenyl-2,3,4,5-tetrahydro-1H-2,3-benzodiazepin-1-one (2a)
M.p. 132–135◦C. Yield 80%. 1H NMR (DMSO-d6, 300 MHz): 2.89–2.94 (1H, m, CH);
3.18–3.22 (1H, m, CH); 4.22–4.23 (1H, m, CH); 5.46 (1H, m, NH); 7.23–7.49 (8H, m, CH);
7.64–7.69 (1H, m, CH); 9.15 (1H, s, NH). 13C NMR (DMSO-d6, 75 MHz): 30.11; 63.85; 126.60;
126.64; 126.78; 128.02; 128.80; 130.66; 135.31; 136.74; 143.22; 174.46 (C=O).
4.1.3. 4-(4’-Methoxyphenyl)-2,3,4,5-tetrahydro-1H-2,3-benzodiazepin-1-one (2b)
M.p. 135–138◦C. Yield 80%. 1H NMR (DMSO-d6, 300 MHz): 2.86–2.92 (1H, m, CH);
3.18–3.23 (1H, m, CH); 3.75 (3H, s, OCH3); 4.21–4.27 (1H, m, CH); 5.37 (1H, m, NH); 6.89
(2H, d, J = 8Hz); 7.30 (1H, d, J = 8); 7.35 (2H, d, J = 8); 7.40(1H, t, J = 8); 7.47 (1H, t, J = 8);
7.65 (1H, t, J = 8); 9.12 (1H, s, NH). 13C NMR (DMSO-d6, 75 MHz): 30.11; 63.85; 126.60;
126.64; 126.78; 128.02; 128.80; 130.66; 135.31; 136.74; 143.22; 174.46 (C=O).
4.1.4. 4-(2,5-Dimethoxyphenyl)-2,3,4,5-tetrahydro-1H-2,3-benzodiazepin-1-one (2c)
M.p. 105–107◦C. Yield 85%. 1H NMR (DMSO-d6, 300 MHz): 2.75–2.80 (1H, m, CH);
3.08–3.12 (1H, m, CH2); 3.75 (3H, s, OCH3); 3.80 (3H, s, OCH3); 4.34–4.39 (1H, m, CH);
5.37 (1H, br.s, NH); 6.44–6.47 (1H, m, CH); 6.54–6.55 (1H, m, CH); 7.20–7.22 (1H, m, CH);
7.20–7.47 (3H, m, CH); 7.63–7.64 (1H, m, CH); 9.15 (1H, s, NH). 13C NMR (DMSO-d6,
75 MHz): 55.10 (CH3); 55.45 (CH3); 57.91 (CH2); 90.86; 104.28; 126.60; 127.43; 128.62; 128.68;
130.62; 135.29; 136.92; 156.52; 159.22; 174.37 (C=O).
4.2. Animals
Male Swiss mice (weighing 25–35 g) from the Pasteur Institute (Rabat, Morocco), were
used for the tests. The animals were caged in groups of 20 mice/cage, at room temperature
of 23 ± 2 ◦C, with free access to tap water and food under a 12:12 h light/dark cycle (lights
on at 06:00 a.m.). All manipulations were carried out between 8:00 a.m. and 3:00 p.m., and
each animal was used only once.
All the experimental procedures were carried out in compliance with the biosecurity
clauses stipulated by the ethical guidelines on animal experimentation to guarantee the
use of the laboratory animals under optimal conditions and, at the same time, to ensure
the animal’s safety. All surgical equipment and operating room storage devices were
autoclaved before each use.
The concept of 3R (Reduce, Refine, Replace) established by Russel and Burch in
1959 [29] was taken into account when planning the experiments. With respect to the
principle, we used a smaller number of animals in each experimental group. Moreover,
euthanasia was carried out under anesthesia to minimize the animal’s suffering.
4.3. Anxiety: Acute and Subacute Treatment
4.3.1. Acute Treatment
The unique oral administration of the vehicle (2% Tween 20, NaCl, 10.0 mL/kg),
bromazepam (the reference drug, 1.0 mg/kg), and VBZ102 (0.5, 1.0 and 10.0 mg/kg) was
carried out for three groups of five animals.
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4.3.2. Subacute Treatment
The oral administration of the vehicle (2% Tween 20, NaCl, 10.0 mL/kg), bromazepam
(1.0 mg/kg), and VBZ102 (1.0 and 10.0 mg/kg) was carried out for three groups of five
animals once a day for 21 days
4.4. Behavioral Tests
4.4.1. Open Field Test
The test was used to evaluate anxiety, exploration, and locomotion. After 60 min of
the drug or vehicle administration, the test was performed by placing each mouse in a
center square to explore the arena and the numbers of ambulation, rearing, and crossing of
the central squares were recorded using a digital video camera [30,31].
Central squares are those that are not adjacent to the arena walls [32]. The square
number was counted when the mouse entered a square with all four paws [33]. Ambulation
means the total number of squares crossed by the mouse, and the crossing of the central
square is the number of times the mouse entered the central squares with all its four
paws [34].
4.4.2. Light–Dark Box Test (LDB)
The light–dark box was a wooden box with dimensions of 44 × 21 × 21 cm and was
divided into two compartments: the first one was painted black inside and covered with a
wooden lid, and the second one was painted white. The two compartments were separated
by a wooden blank, having a hole of 7 × 7 cm in the center at the floor level.
After 60 min of the drug or vehicle administration, a 5 min test was performed
by placing each mouse in the center of the dark box [35], keeping its face away from
the opening hole. The number of transitions and time spent in each compartment were
recorded using a digital video camera [36].
4.4.3. Novel Object Recognition Test
The distinction between familiar and unfamiliar objects is an index of recognition
memory. The measurement is based on an innate preference of rodents for novel objects
over familiar ones [37,38].
The mice were divided into three groups of five animals and received an oral dose
of the vehicle (2% Tween 20, NaCl, 10.0 mL/kg), bromazepam (1.0 mg/kg), or VBZ102
(10.0 mg/kg) treatment on day 21. After 60 min of the drug or vehicle administration,
the training trial was performed. The mice were placed in a 52 × 52 × 25 cm box and
allowed to explore two identical objects for 5 min each. The training was repeated twice.
The test trial was performed 24 h after the training. Then, one of the two familiar objects
(F) was replaced with a new one (N), and the mice were allowed to explore them for 5 min.
Discrimination index D was used as a measure of the object recognition [39]:
DI =
Tn − T f
Tn + T f
(1)
where Tn is the exploration time devoted to the novel object, and Tf is the exploration time
devoted to the familiar object.
4.5. Toxicity
Body weight and local injuries were studied throughout the treatment. Mortality,
if any, was recorded in all groups during the treatment. At the end of the treatment
(28 days), biochemical (liver and renal function assays) and histological parameters were
investigated. The organs were quickly blotted, weighed on a digital balance, and processed
for histological studies. The organ/body weight ratio was calculated for each organ, and
tissues were processed by H&E staining [40].
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4.5.1. Biochemical Parameters
Biochemical assays (urea, creatinine, alanine aminotransferase (ALT), aspartate amino-
transferase (AST)) were performed using the blood plasma and Randox kits at the end of
the assay [41,42].
4.5.2. Histological Examination
At the end of the treatment, the animals were euthanized, and several organs, e.g.,
liver, kidneys, and brain were collected for histological examinations. All the organs
were immediately fixed in 10% buffered formalin and processed with H&E staining for
histology [43,44].
4.6. Statistical Analyses
Statistical analysis was performed in GraphPad Prism software using a one-way
ANOVA followed by Dunnett’s post hoc test to describe the toxicity results and a two-way
ANOVA followed by Tukey’s post hoc test to describe the results of anxiety and memory
tests (p < 0.05).
5. Conclusions
We propose a new synthetic approach to 2,5-dihydro-1H-2,3-benzodiazepin-1-ones.
One representative of the newly synthesized diazepines, viz. the 4-(4-methoxyphenyl)-
2,3,4,5-tetrahydro-2,3-benzodiazepin-1-one (VBZ102), was tested for CNS activity and
side-effects in mice. It was shown that it has a pronounced anxiolytic-like effect in different
model experiments without provoking memory impairments and compromising the motor
activity and biochemical parameters of the experimental animals. Unlike other benzodi-
azepines (e.g., bromazepam), a sedative effect was noted only after administration of the
VBZ102 at 10.0 mg/kg.
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